Skip to main content
. 2021 Nov 23;9(4):E1055–E1062. doi: 10.9778/cmajo.20210091

Table 1:

Adjustment factors for biologic prices

Biologic Primary analysis: adjustment factor, % Policy consideration #1: include insulin glargine, % Policy consideration #2: include biosimilar for adalimumab, % Policy consideration #3: negotiated price reductions below threshold, %
Etanercept 62.0 62.8 62.8 75, 50
Infliximab 53.2 53.2 53.2 75, 50
Adalimumab NA NA 60.0 75, 50
Insulin glargine NA 75.0 NA NA

Note: NA = not applicable.